On this page
Chromosome 18
Gene-sparse - but carries SMAD4 (juvenile polyposis) and is the chromosome of Edwards syndrome (trisomy 18).
Schematic of chromosome 18 showing the short (p) and long (q) arms. Arm ratio per GRCh38 - banding schematic.
Available at Jeen Health
Clinical tests that include this
Overview
Chromosome 18 represents roughly 2.5 per cent of the human genome, with a total length of 80.4 million base pairs. It is classified as submetacentric, meaning its centromere sits off-centre so that the short arm (designated 18p) is noticeably shorter than the long arm (18q). Despite its relatively large physical size, chromosome 18 carries only around 268 protein-coding genes, making it one of the more gene-sparse chromosomes in the human karyotype.
Clinically, chromosome 18 is recognised for two main reasons: whole-chromosome trisomy 18, which causes Edwards syndrome, and pathogenic variants in genes such as SMAD4 that lead to rare inherited conditions. Edwards syndrome is the second commonest autosomal trisomy compatible with live birth, after Down syndrome, and is typically identified through prenatal screening programmes offered by the NHS. In addition to trisomy, partial deletions or duplications of 18q can result in developmental delay and congenital abnormalities, though these are less frequently encountered than the whole-chromosome aneuploidy.
The gene-sparse nature of chromosome 18 does not diminish its clinical importance. Several genes on the long arm play pivotal roles in growth-factor signalling, cell-junction integrity, and apoptosis regulation, and their disruption is associated with hereditary cancer syndromes, cardiovascular disease, and neurodevelopmental disorders.
Structure
Like all human chromosomes, chromosome 18 consists of a single linear molecule of DNA wrapped around histone proteins to form nucleosomes, which in turn coil into progressively denser chromatin fibres. During cell division, this chromatin condenses into the compact X-shaped structure visible under a microscope at metaphase. The centromere of chromosome 18 lies closer to one end than the other, creating a short p arm and a longer q arm. This submetacentric architecture means the chromosome can be reliably identified by karyotyping based on its banding pattern and overall proportions.
The long arm, 18q, is where most of the chromosome's coding sequence resides. The short arm, 18p, is relatively gene-poor and contains stretches of repetitive DNA. Neither arm harbours ribosomal RNA gene clusters, a feature that distinguishes chromosome 18 from the acrocentric chromosomes. The DNA sequence of chromosome 18 was among those completed during the Human Genome Project, providing a reference map that underpins modern clinical genomic testing, including chromosomal microarray analysis for deletions and duplications.
Video: NIPT statistics explained
Notable regions
The cytogenetic band 18q21.2 is of particular clinical significance because it is home to SMAD4. This gene encodes a protein that acts as a central hub in signalling pathways governed by transforming growth factor beta superfamily members. When pathogenic variants disrupt SMAD4 function, affected individuals may develop juvenile polyposis syndrome, characterised by multiple polyps in the gastrointestinal tract and an elevated risk of colorectal and gastric cancer. Some SMAD4 variants also give rise to a combined syndrome that overlaps with hereditary haemorrhagic telangiectasia, a disorder marked by abnormal blood-vessel formation leading to nosebleeds, arteriovenous malformations, and other vascular complications. Because SMAD4-related conditions confer cancer predisposition, affected families are often referred to regional NHS genomic medicine centres for surveillance colonoscopy and genetic counselling.
Further along the long arm, at 18q21.33, lies BCL2, a gene that regulates programmed cell death. The BCL2 protein inhibits apoptosis, helping cells survive in the face of stress or damage. While germline variants in BCL2 are not commonly associated with inherited disease, the gene is frequently implicated in cancer through somatic rearrangements. The t(14;18) translocation, which juxtaposes BCL2 with immunoglobulin heavy-chain regulatory elements on chromosome 14, is a hallmark of follicular lymphoma and is detected by cytogenetic or molecular testing in haematology laboratories. This translocation leads to overexpression of BCL2, allowing malignant B cells to evade normal death signals.
Other regions of chromosome 18 contain genes involved in diverse biological processes. The desmosomal genes DSC2 and DSG2, located at 18q12.1, encode proteins that form the adhesive junctions between heart-muscle cells. Pathogenic variants in either gene can cause arrhythmogenic right ventricular cardiomyopathy, a condition in which the heart's right ventricle becomes infiltrated with fibrous and fatty tissue, predisposing to life-threatening arrhythmias. These disorders underscore the clinical breadth of chromosome 18, from cancer predisposition to structural heart disease.
Notable genes
SMAD4 is the standout gene on chromosome 18 in terms of inherited disease burden. It is central to the signalling cascades that control cell growth, differentiation, and tissue patterning during development and throughout life. Pathogenic variants in SMAD4 disrupt these regulatory networks, leading to uncontrolled polyp formation in the gastrointestinal tract and an increased risk of malignancy. Families with SMAD4 pathogenic variants are offered personalised surveillance strategies through NHS clinical genetics services, including regular endoscopy from adolescence onward.
BCL2, though more commonly altered somatically in cancer, remains a gene of interest for researchers exploring how cells decide between survival and death. DSC2 and DSG2 illustrate the importance of structural proteins in maintaining cardiac integrity; their role in arrhythmogenic cardiomyopathy has led to the inclusion of these genes in cardiomyopathy gene panels used across NHS genomic laboratories. GNAL, positioned at 18p11.21, encodes a G-protein subunit involved in dopamine signalling and has been linked to certain movement disorders. Lastly, NPC1, which resides on chromosome 18, is associated with Niemann-Pick disease type C, a rare lysosomal storage disorder affecting cholesterol transport within cells. Collectively, these genes demonstrate that even a chromosome with relatively few genes can harbour loci critical to human health.
Chromosomal disorders
Edwards syndrome, caused by trisomy 18, is the defining chromosomal disorder of this chromosome. It arises when an error during meiosis results in three copies of chromosome 18 instead of the usual two. The additional genetic material disrupts normal development across multiple organ systems, leading to characteristic features such as a small head, clenched hands with overlapping fingers, congenital heart defects, and kidney abnormalities. Many affected pregnancies end in miscarriage, and most infants who survive to birth face life-limiting conditions (meaning most do not survive beyond the first year of life). Trisomy 18 is typically a de novo event, meaning it occurs sporadically rather than being inherited from a parent, though advanced maternal age is associated with a higher risk.
In addition to whole-chromosome trisomy, partial deletions of the long arm (18q deletion syndrome) can occur. Individuals with 18q deletions present with developmental delay, short stature, and variable dysmorphic features. The severity and specific constellation of findings depend on the size and location of the deleted segment. Chromosomal microarray analysis, routinely available through NHS genomic laboratories, can precisely map the extent of such deletions and help clinicians predict which genes are affected. Unlike trisomy 18, 18q deletions are compatible with survival into adulthood, though affected individuals typically require multidisciplinary support.
Partial duplications of chromosome 18 are less common but have been reported. As with deletions, the clinical impact depends on the region involved and the size of the duplication. These rarer imbalances are usually identified when a child undergoes genetic testing for unexplained developmental concerns. Because many chromosomal rearrangements arise from balanced translocations in a parent, families are often offered parental karyotyping to assess recurrence risk and inform reproductive choices.
Prenatal screening & diagnosis
Trisomy 18 is one of the three commonest autosomal aneuploidies screened for during pregnancy in the NHS. Non-invasive prenatal testing, which analyses cell-free foetal DNA circulating in maternal blood from around 10 weeks of gestation, can detect trisomy 18 with high sensitivity. NIPT is offered as a follow-up test to women who receive a higher-chance result from the combined first-trimester screening, which integrates maternal age, nuchal translucency measurement on ultrasound, and biochemical markers in maternal serum. If NIPT suggests trisomy 18, diagnostic testing by chorionic villus sampling (CVS) or amniocentesis is offered to confirm the result through karyotype or chromosomal microarray analysis.
Ultrasound examination may reveal features suggestive of trisomy 18, such as intrauterine growth restriction, polyhydramnios, or structural anomalies of the heart, kidneys, or skeleton. These findings often prompt referral to a foetal medicine specialist and discussion of further testing. The NHS Fetal Anomaly Screening Programme provides a framework for identifying such abnormalities during the routine 18- to 21-week anatomy scan. Following a confirmed diagnosis of trisomy 18, parents are offered counselling to discuss the prognosis, management options, and available support, in a manner that respects their autonomy and values.
For families with a history of 18q deletion or other structural rearrangements involving chromosome 18, preimplantation genetic testing or early prenatal diagnosis may be considered in future pregnancies. These options are discussed within the context of NHS clinical genetics consultations, where counsellors provide tailored information about recurrence risks and testing strategies.
Inheritance & recurrence
Trisomy 18 is almost always a de novo occurrence, arising from meiotic nondisjunction in the formation of egg or sperm. The recurrence risk for parents who have had one child with trisomy 18 is low, generally quoted as around 1 per cent in subsequent pregnancies, which is slightly higher than would be expected for the mother's age alone. Advanced maternal age is the most consistent risk factor for trisomy 18, as it is for other aneuploidies. Families who experience a pregnancy affected by trisomy 18 are typically referred to clinical genetics or foetal medicine services for counselling, where the mechanism of the trisomy and options for future pregnancies are explained in a supportive environment.
In contrast, 18q deletions and other structural rearrangements may be inherited from a parent carrying a balanced translocation. If a parent has a balanced rearrangement involving chromosome 18, the risk of having a child with an unbalanced karyotype can be substantially higher than the general-population risk, though the exact figure depends on the specific translocation and the sex of the transmitting parent. Parental karyotyping is therefore an important step in the evaluation of a child with a chromosomal imbalance. When a parental rearrangement is identified, genetic counselling addresses recurrence risks, the option of prenatal diagnosis in future pregnancies, and, in some cases, preimplantation genetic testing for monogenic and chromosomal disorders.
For single-gene conditions linked to chromosome 18, such as juvenile polyposis syndrome caused by SMAD4 variants, inheritance typically follows an autosomal dominant pattern. Each child of an affected parent has a 50 per cent chance of inheriting the pathogenic variant. Predictive testing and cascade screening of at-risk relatives are coordinated through NHS regional genetics services, ensuring that appropriate surveillance and preventive measures are offered to those who carry a pathogenic variant.
Frequently asked questions
What is Edwards syndrome and how common is it?
Edwards syndrome is the condition caused by having three copies of chromosome 18 instead of two, known as trisomy 18. It occurs in roughly 1 in 5,000 live births, though many affected pregnancies result in miscarriage. Most cases arise sporadically due to a random error during egg or sperm formation, and the risk increases with maternal age.
Can Edwards syndrome be detected before birth?
Yes. The NHS offers screening through non-invasive prenatal testing, which can detect trisomy 18 from a maternal blood sample taken from around 10 weeks of pregnancy. If the screening result suggests a higher chance of trisomy 18, diagnostic testing such as amniocentesis or chorionic villus sampling is offered to confirm the result by analysing foetal cells.
What does it mean if my child has a deletion of part of chromosome 18?
A deletion of part of chromosome 18, often called 18q deletion syndrome, means a small piece of the chromosome is missing. The effects vary depending on the size and location of the deletion, but may include developmental delay, growth difficulties, and subtle differences in physical features. Chromosomal microarray testing can map exactly which genes are lost, helping clinicians anticipate support needs.
Are conditions caused by chromosome 18 gene changes inherited?
Trisomy 18 is almost always a random event and not inherited. However, deletions or duplications of chromosome 18 can sometimes be inherited if a parent carries a balanced chromosomal rearrangement. For single-gene disorders such as juvenile polyposis due to SMAD4 variants, inheritance is typically autosomal dominant, meaning there is a 50 per cent chance of passing the variant to each child.
If I have a higher-chance screening result for trisomy 18, what happens next?
You will be offered an appointment with a foetal medicine specialist or midwife to discuss the result and the option of diagnostic testing, such as amniocentesis, to confirm whether trisomy 18 is present. The decision to proceed with further testing is entirely yours, and you will receive support and information to help you make the choice that feels right for you and your family.
Launch-set genes on chromosome 18
Genes on this chromosome that currently have dedicated pages in the library. This list grows as we publish more.